Acadia Pharmaceutica (ACAD)

$14.73 -0.10 (-0.67%)
Market Cap 2.47B
Revenue (ttm) 957.80M
Net Income (ttm) 226.45M
EPS (ttm) N/A
PE Ratio 21.42
Forward PE 23.43
Profit Margin 23.64%
Debt to Equity Ratio 0.00
Volume 957,500
Avg Vol 1,725,328
Day's Range N/A - N/A
Shares Out 166.79M
Stochastic %K 59%
Beta 0.54
Analysts Sell
Price Target $24.70

Latest News on ACAD

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 4:05 PM EDT - 2 days ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 11, 2025, 4:05 PM EDT - 14 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Mar 13, 2025, 4:05 PM EDT - 6 weeks ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 5, 2025, 9:05 AM EST - 7 weeks ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 3, 2025, 9:05 AM EST - 7 weeks ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Mar 2, 2025, 5:19 AM EST - 7 weeks ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:13 PM EST - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 26, 2025, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:05 AM EST - 3 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Jan 14, 2025, 9:00 AM EST - 3 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Dec 19, 2024, 4:05 PM EST - 4 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Dec 11, 2024, 4:05 PM EST - 4 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Dec 9, 2024, 9:00 AM EST - 4 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 27, 2024, 3:18 PM EST - 5 months ago

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Nov 26, 2024, 4:05 PM EST - 5 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 11, 2024, 10:50 AM EST - 5 months ago

Acadia Pharmaceuticals: Proving The Naysayers Wrong

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 8:09 PM EST - 6 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Nov 6, 2024, 4:05 PM EST - 6 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Nov 5, 2024, 4:05 PM EST - 6 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Oct 17, 2024, 6:41 PM EDT - 6 months ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Oct 16, 2024, 4:07 PM EDT - 6 months ago

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Sep 23, 2024, 4:15 PM EDT - 7 months ago

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Sep 19, 2024, 12:00 PM EDT - 7 months ago

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 26, 2024, 3:02 PM EDT - 8 months ago

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Ryan Reynolds Announces More to Parkinson's® Campaign

Aug 14, 2024, 8:04 AM EDT - 9 months ago

Ryan Reynolds Announces More to Parkinson's® Campaign

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 4:30 PM EDT - 9 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:15 PM EDT - 9 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Aug 6, 2024, 4:05 PM EDT - 9 months ago

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Jul 24, 2024, 4:05 PM EDT - 9 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Jul 18, 2024, 9:04 AM EDT - 10 months ago

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals: Back In The Buy Zone

Jun 23, 2024, 11:32 AM EDT - 10 months ago

Acadia Pharmaceuticals: Back In The Buy Zone

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Jun 18, 2024, 9:04 AM EDT - 11 months ago

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings

Jun 18, 2024, 9:00 AM EDT - 11 months ago

New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings

Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments

Jun 5, 2024, 11:46 PM EDT - 11 months ago

Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

May 15, 2024, 9:05 AM EDT - 1 year ago

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:00 PM EDT - 1 year ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

May 8, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Apr 29, 2024, 4:16 PM EDT - 1 year ago

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Apr 22, 2024, 9:04 AM EDT - 1 year ago

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D.

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D.

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference